Rockwell Medical Inc. (RMTI)
1.26
-0.09 (-6.67%)
At close: Mar 24, 2025, 3:59 PM
-6.67% (1D)
| Bid | 1.26 |
| Market Cap | 40.88M |
| Revenue (ttm) | 101.32M |
| Net Income (ttm) | -1.27M |
| EPS (ttm) | -0.03 |
| PE Ratio (ttm) | -42.17 |
| Forward PE | 30 |
| Analyst | Buy |
| Ask | 1.27 |
| Volume | 553,379 |
| Avg. Volume (20D) | 277,741 |
| Open | 1.35 |
| Previous Close | 1.35 |
| Day's Range | 1.26 - 1.36 |
| 52-Week Range | 1.26 - 5.15 |
| Beta | 1.56 |
About RMTI
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stor...
Sector Healthcare
IPO Date Jan 27, 1998
Employees 237
Stock Exchange NASDAQ
Ticker Symbol RMTI
Website https://www.rockwellmed.com
Analyst Forecast
According to 2 analyst ratings, the average rating for RMTI stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 216.21% from the latest price.
Stock ForecastsEarnings Surprise
Rockwell Medical has released their quartely earnings
on Mar 20, 2025:
5 days ago
-20.45%
Rockwell Medical shares are trading lower. The com...
Unlock content with
Pro Subscription
3 months ago
+10.45%
Rockwell Medical shares are trading higher after the company announced expectations for $10 million in FY25 net sales and entered a purchase agreement with a provider of dialysis products and services.
